alexa Psoriasis|omicsgroup|Journal Of Aging Science

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Journal of Aging Science is one of the open access journals in in the field of Aging. The open access policy of the journals aims at increasing the visibility and accessibility of the published content and thus providing the desirable researches to the readers. It mainly provides information regarding aging, reproductive aging, aging skin, biomarkers of aging, cognitive-aging, dementia, frailty, healthy-aging, geriatrics. Treatment of psoriasis with infliximab is effective and relatively safe. Its advantages are weight-based dosing, the possibility to reduce the interval or to increase the dose, the very well set up induction phase of treatment and the intravenous administration. The disadvantage is the occurrence of infusion reactions and the secondary treatment failure – in both cases often caused by the production of antibodies to infliximab. Another disadvantage is a relatively high cost of treatment, especially in patients with higher body weight. Therefore, it is very important to have objective indicators of treatment efficacy. Andrea Kovacikova Curkova, Management of Infliximab Treated Patients with Psoriasis Based On Infliximab Plasma Levels and Antibodies to Infliximab. OMICS Group is among best open access publishers with expert reviewers and renowned scientists in its Editorial Board. Both editors and reviewers actively participate in the peer-review process and help in completing the review process within 21 days. Apart from this OMICS Group organizes more than 3000+ International Scientific Conferences.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on September, 2020